Discovery PESTLE Analysis
Your Competitive Advantage Starts with This Report
Unlock strategic clarity with our PESTLE Analysis of Discovery—three expert-level insights into political, economic, social, technological, legal and environmental forces shaping the company. Perfect for investors, consultants and strategists, it’s ready-to-use and editable. Buy the full report now for the complete, actionable breakdown.
Political factors
South Africa NHI and health policy direction
NHI legislation and public–private reforms could reshape risk pools, compress pricing and reconfigure provider networks, affecting private cover that serves approximately 16% of the population (~9 million) and a health sector spending near 8–9% of GDP. For Discovery this pressures medical-scheme administration fees, hospital and clinician contracts and claims management. Scenarios range from phased rollout to rapid shifts, creating implementation uncertainty and timing risk. Expect increased lobbying, compliance spend and product redesign to align with new contracting and reimbursement models.
UK health policy and regulator stance
UK health policy and regulator stance reshapes PMI and wellness: NHS England's 2024/25 budget of about £192bn and a waiting list exceeding 7.5m sustain demand for PMI and cash plans, with private cover reaching roughly 10% of the population. FCA Consumer Duty (effective July 2023) and PRA expectations on conduct and fair value increase compliance costs and product governance requirements. Political shifts affecting NHS procurement or vertical integration could expand or constrain partnership and outsourcing opportunities for insurers and providers.
Government incentives for wellness and prevention
Tax incentives and subsidies that lower costs for screenings, vaccinations and fitness programs can raise preventive uptake; WHO reports NCDs cause ~41 million deaths annually (71% of deaths, 2021). Discovery’s shared-value Vitality model, active across 24 markets as of 2024, links rewards to behavior to improve adherence and reduce claims. Public–private partnerships can scale screening and lifestyle programs to cut NCD burden, but success hinges on alignment with budget cycles and rising political appetite for prevention-led savings.
Geopolitical risk and market entry approvals
Geopolitical risk, sanctions and licensing materially shape Discovery’s international expansion: FDA median review ~10 months and EMA centralized review ~210 days set baselines, while 194 WHO member states have divergent regimes; 2024 saw over 30 national elections increasing policy reversal risk, requiring active engagement with regulators and health ministries and contingency plans for sudden regulatory shifts.
- Regulatory timelines: FDA 10m, EMA 210d
- Global scope: 194 WHO states
- Political volatility: 30+ elections in 2024
- Mitigation: regulator/health ministry engagement, contingency planning
FX controls and fiscal policy in core markets
South African exchange controls (R1m annual discretionary allowance), corporate tax 27% and VAT 15%, plus a 5yr CDS ~350bps and 10y bond ~10.5% (mid‑2025), constrain capital mobility and increase dividend repatriation/friction; sovereign risk raises hedging costs and repatriation timing.
- Fiscal tightening: lowers affordability, cuts discretionary spend
- Stimulus: boosts consumption, raises short‑term demand
- Sin taxes: raise prices, reduce consumption, may improve public health
- Treasury: stress tests, pre‑funding, FX hedges, capital planning
NHI reforms, NHS pressure, regulatory delays and SA capital controls risk
NHI reforms, UK NHS pressures and global regulatory timelines (FDA 10m, EMA 210d) create implementation, compliance and contracting risk for Discovery; private cover ~16% (~9m) and health spend ~8–9% GDP amplify market impact. Geopolitical volatility (30+ elections 2024) and SA capital controls (R1m allowance, corp tax 27%, VAT 15%) raise expansion and repatriation costs.
| Metric | Value |
|---|---|
| Private cover (SA) | 16% (~9m) |
| NHS budget 24/25 | £192bn |
| FDA/EMA | 10m / 210d |
| SA tax/controls | Corp 27% VAT 15% R1m |
What is included in the product
Detailed Word Document
Explores how Political, Economic, Social, Technological, Environmental and Legal forces uniquely impact Discovery, with data-backed trends and forward-looking insights to help executives, consultants, and investors identify risks, opportunities, and strategy implications.
Customizable Excel Spreadsheet
A concise, visually segmented PESTLE summary for Discovery that streamlines stakeholder alignment and meeting prep and can be dropped into slides or reports; editable notes let teams tailor insights to region or business line for faster decision-making.
Economic factors
Consumer income and affordability cycles
Consumer income cycles shape lapse rates and product mix: IMF WEO 2025 shows 2024 GDP growth of ~0.8% in South Africa, ~0.3% in the UK and ~3.5% in other EMs, while CPI averaged ~5.8% (SARB) in SA and ~3% (ONS) in the UK, squeezing disposable income and increasing lapses in mid/low-tier products. Scenario models calibrated to 2024 real-wage moves (UK real wages ~+2% y/y; SA stagnation) imply ~0.8 percentage-point rise in lapse rates per -1% real-wage fall and ~0.5–1.2% premium sensitivity, reducing Vitality engagement ~0.6% per -1% real wage; this dictates prioritising flexible pricing and broker/direct digital push where elasticity is highest.
Medical inflation and claims trajectory
South African medical inflation ran near 8–9% in 2024 versus general CPI about 5–6%, lifting Discovery Health loss ratios; utilization rose as elective procedures rebounded ~15% post‑COVID while chronic disease (diabetes/hypertension) prevalence remains elevated (~10–12% adults). Provider tariff negotiations and benefit design levers (formularies, co‑pays) are key; stress tests show a 6–8ppt claims shock could erode margins ~2–3ppt.
Interest rates and investment returns
Interest rate levels drive investment income and set reserving discount rates—US 10‑yr at ~4.2% (June 2025) lifts asset yields and reduces PV of liabilities, improving solvency coverage. Balance sheet duration matching and asset allocation must extend duration into corporates and long govies to hedge liability curves and reduce capital volatility. Guaranteed products and annuities face margin pressure; stress tests assuming a 100 bps cut or a 50–150 bps parallel yield‑curve shift model reserve increases and capital strain.
Employment trends and group benefits demand
Rising unemployment in South Africa (≈33% in 2024) depresses corporate scheme membership and premium volumes as SME take-up falls faster than large corporates; large employers retain group schemes, supporting stable premium pools while SMEs shift to cost‑saving flexible benefits. Wage bills rose ~6% y/y in 2024, driving demand for benefits that control total rewards; employers report wellness programmes deliver ROI in the region of 3:1 to 6:1. Pipeline scenarios: tight labour markets boost uptake and premium growth 3–7% annually; weak labour markets shift volumes toward scaled, modular offerings.
- Employment impact: high unemployment → lower SME membership, stable large-corp retention
- Wage pressure: ~6% wage growth → demand for cost-effective benefits
- Wellness ROI: 3:1–6:1 supports employer investment
- Forecast: tight market +3–7% premiums; weak market → modular SME offerings
Currency volatility and translation risk
Currency moves in ZAR and GBP materially affect Discovery’s reported rand revenues and capital when translating UK earnings and dollar-priced tech costs; USD/ZAR around 18.5 and GBP/ZAR ~23.5 (mid-2025) amplify translation losses on a weaker ZAR.
Hedging policies use forwards and natural offsets from UK liabilities and local underwriting; procurement in hard currency raises operating cost exposure for tech and reinsurers.
Scenario: sustained 20% ZAR depreciation would reduce reported rand equity and inflate imported tech costs materially; volatility spikes increase hedging costs and earnings variance.
- Translation risk: high
- Hedging: active forwards
- Hard-currency procurement: significant
- 20% ZAR fall: material P&L/equity impact
NHI reforms, NHS pressure, regulatory delays and SA capital controls risk
Macroeconomic squeeze: 2024 GDP growth ~0.8% (ZA), ~0.3% (UK) with CPI ~5.8% (ZA) and ~3% (UK) reducing real incomes and raising lapses; calibrated models show ~0.8ppt lapse rise per -1% real‑wage fall. Medical inflation ~8–9% in 2024, lifting loss ratios; SA unemployment ~33% cuts SME scheme volumes. FX and rates: USD/ZAR ~18.5, GBP/ZAR ~23.5 (mid‑2025); US 10yr ~4.2%.
| Metric | Value |
|---|---|
| SA GDP growth (2024) | ~0.8% |
| UK GDP (2024) | ~0.3% |
| CPI SA/UK | 5.8% / 3% |
| Medical inflation (SA 2024) | 8–9% |
| Unemployment SA (2024) | ≈33% |
| USD/ZAR (mid‑2025) | ~18.5 |
| US 10yr (Jun‑2025) | ~4.2% |
What You See Is What You Get
Discovery PESTLE Analysis
The preview shown here is the exact Discovery PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use. What you see is the final file with no placeholders or teasers. After checkout you’ll be able to download this exact document immediately.
Your Competitive Advantage Starts with This Report
Unlock strategic clarity with our PESTLE Analysis of Discovery—three expert-level insights into political, economic, social, technological, legal and environmental forces shaping the company. Perfect for investors, consultants and strategists, it’s ready-to-use and editable. Buy the full report now for the complete, actionable breakdown.
Political factors
South Africa NHI and health policy direction
NHI legislation and public–private reforms could reshape risk pools, compress pricing and reconfigure provider networks, affecting private cover that serves approximately 16% of the population (~9 million) and a health sector spending near 8–9% of GDP. For Discovery this pressures medical-scheme administration fees, hospital and clinician contracts and claims management. Scenarios range from phased rollout to rapid shifts, creating implementation uncertainty and timing risk. Expect increased lobbying, compliance spend and product redesign to align with new contracting and reimbursement models.
UK health policy and regulator stance
UK health policy and regulator stance reshapes PMI and wellness: NHS England's 2024/25 budget of about £192bn and a waiting list exceeding 7.5m sustain demand for PMI and cash plans, with private cover reaching roughly 10% of the population. FCA Consumer Duty (effective July 2023) and PRA expectations on conduct and fair value increase compliance costs and product governance requirements. Political shifts affecting NHS procurement or vertical integration could expand or constrain partnership and outsourcing opportunities for insurers and providers.
Government incentives for wellness and prevention
Tax incentives and subsidies that lower costs for screenings, vaccinations and fitness programs can raise preventive uptake; WHO reports NCDs cause ~41 million deaths annually (71% of deaths, 2021). Discovery’s shared-value Vitality model, active across 24 markets as of 2024, links rewards to behavior to improve adherence and reduce claims. Public–private partnerships can scale screening and lifestyle programs to cut NCD burden, but success hinges on alignment with budget cycles and rising political appetite for prevention-led savings.
Geopolitical risk and market entry approvals
Geopolitical risk, sanctions and licensing materially shape Discovery’s international expansion: FDA median review ~10 months and EMA centralized review ~210 days set baselines, while 194 WHO member states have divergent regimes; 2024 saw over 30 national elections increasing policy reversal risk, requiring active engagement with regulators and health ministries and contingency plans for sudden regulatory shifts.
- Regulatory timelines: FDA 10m, EMA 210d
- Global scope: 194 WHO states
- Political volatility: 30+ elections in 2024
- Mitigation: regulator/health ministry engagement, contingency planning
FX controls and fiscal policy in core markets
South African exchange controls (R1m annual discretionary allowance), corporate tax 27% and VAT 15%, plus a 5yr CDS ~350bps and 10y bond ~10.5% (mid‑2025), constrain capital mobility and increase dividend repatriation/friction; sovereign risk raises hedging costs and repatriation timing.
- Fiscal tightening: lowers affordability, cuts discretionary spend
- Stimulus: boosts consumption, raises short‑term demand
- Sin taxes: raise prices, reduce consumption, may improve public health
- Treasury: stress tests, pre‑funding, FX hedges, capital planning
NHI reforms, NHS pressure, regulatory delays and SA capital controls risk
NHI reforms, UK NHS pressures and global regulatory timelines (FDA 10m, EMA 210d) create implementation, compliance and contracting risk for Discovery; private cover ~16% (~9m) and health spend ~8–9% GDP amplify market impact. Geopolitical volatility (30+ elections 2024) and SA capital controls (R1m allowance, corp tax 27%, VAT 15%) raise expansion and repatriation costs.
| Metric | Value |
|---|---|
| Private cover (SA) | 16% (~9m) |
| NHS budget 24/25 | £192bn |
| FDA/EMA | 10m / 210d |
| SA tax/controls | Corp 27% VAT 15% R1m |
What is included in the product
Detailed Word Document
Explores how Political, Economic, Social, Technological, Environmental and Legal forces uniquely impact Discovery, with data-backed trends and forward-looking insights to help executives, consultants, and investors identify risks, opportunities, and strategy implications.
Customizable Excel Spreadsheet
A concise, visually segmented PESTLE summary for Discovery that streamlines stakeholder alignment and meeting prep and can be dropped into slides or reports; editable notes let teams tailor insights to region or business line for faster decision-making.
Economic factors
Consumer income and affordability cycles
Consumer income cycles shape lapse rates and product mix: IMF WEO 2025 shows 2024 GDP growth of ~0.8% in South Africa, ~0.3% in the UK and ~3.5% in other EMs, while CPI averaged ~5.8% (SARB) in SA and ~3% (ONS) in the UK, squeezing disposable income and increasing lapses in mid/low-tier products. Scenario models calibrated to 2024 real-wage moves (UK real wages ~+2% y/y; SA stagnation) imply ~0.8 percentage-point rise in lapse rates per -1% real-wage fall and ~0.5–1.2% premium sensitivity, reducing Vitality engagement ~0.6% per -1% real wage; this dictates prioritising flexible pricing and broker/direct digital push where elasticity is highest.
Medical inflation and claims trajectory
South African medical inflation ran near 8–9% in 2024 versus general CPI about 5–6%, lifting Discovery Health loss ratios; utilization rose as elective procedures rebounded ~15% post‑COVID while chronic disease (diabetes/hypertension) prevalence remains elevated (~10–12% adults). Provider tariff negotiations and benefit design levers (formularies, co‑pays) are key; stress tests show a 6–8ppt claims shock could erode margins ~2–3ppt.
Interest rates and investment returns
Interest rate levels drive investment income and set reserving discount rates—US 10‑yr at ~4.2% (June 2025) lifts asset yields and reduces PV of liabilities, improving solvency coverage. Balance sheet duration matching and asset allocation must extend duration into corporates and long govies to hedge liability curves and reduce capital volatility. Guaranteed products and annuities face margin pressure; stress tests assuming a 100 bps cut or a 50–150 bps parallel yield‑curve shift model reserve increases and capital strain.
Employment trends and group benefits demand
Rising unemployment in South Africa (≈33% in 2024) depresses corporate scheme membership and premium volumes as SME take-up falls faster than large corporates; large employers retain group schemes, supporting stable premium pools while SMEs shift to cost‑saving flexible benefits. Wage bills rose ~6% y/y in 2024, driving demand for benefits that control total rewards; employers report wellness programmes deliver ROI in the region of 3:1 to 6:1. Pipeline scenarios: tight labour markets boost uptake and premium growth 3–7% annually; weak labour markets shift volumes toward scaled, modular offerings.
- Employment impact: high unemployment → lower SME membership, stable large-corp retention
- Wage pressure: ~6% wage growth → demand for cost-effective benefits
- Wellness ROI: 3:1–6:1 supports employer investment
- Forecast: tight market +3–7% premiums; weak market → modular SME offerings
Currency volatility and translation risk
Currency moves in ZAR and GBP materially affect Discovery’s reported rand revenues and capital when translating UK earnings and dollar-priced tech costs; USD/ZAR around 18.5 and GBP/ZAR ~23.5 (mid-2025) amplify translation losses on a weaker ZAR.
Hedging policies use forwards and natural offsets from UK liabilities and local underwriting; procurement in hard currency raises operating cost exposure for tech and reinsurers.
Scenario: sustained 20% ZAR depreciation would reduce reported rand equity and inflate imported tech costs materially; volatility spikes increase hedging costs and earnings variance.
- Translation risk: high
- Hedging: active forwards
- Hard-currency procurement: significant
- 20% ZAR fall: material P&L/equity impact
NHI reforms, NHS pressure, regulatory delays and SA capital controls risk
Macroeconomic squeeze: 2024 GDP growth ~0.8% (ZA), ~0.3% (UK) with CPI ~5.8% (ZA) and ~3% (UK) reducing real incomes and raising lapses; calibrated models show ~0.8ppt lapse rise per -1% real‑wage fall. Medical inflation ~8–9% in 2024, lifting loss ratios; SA unemployment ~33% cuts SME scheme volumes. FX and rates: USD/ZAR ~18.5, GBP/ZAR ~23.5 (mid‑2025); US 10yr ~4.2%.
| Metric | Value |
|---|---|
| SA GDP growth (2024) | ~0.8% |
| UK GDP (2024) | ~0.3% |
| CPI SA/UK | 5.8% / 3% |
| Medical inflation (SA 2024) | 8–9% |
| Unemployment SA (2024) | ≈33% |
| USD/ZAR (mid‑2025) | ~18.5 |
| US 10yr (Jun‑2025) | ~4.2% |
What You See Is What You Get
Discovery PESTLE Analysis
The preview shown here is the exact Discovery PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use. What you see is the final file with no placeholders or teasers. After checkout you’ll be able to download this exact document immediately.
Description
Your Competitive Advantage Starts with This Report
Unlock strategic clarity with our PESTLE Analysis of Discovery—three expert-level insights into political, economic, social, technological, legal and environmental forces shaping the company. Perfect for investors, consultants and strategists, it’s ready-to-use and editable. Buy the full report now for the complete, actionable breakdown.
Political factors
South Africa NHI and health policy direction
NHI legislation and public–private reforms could reshape risk pools, compress pricing and reconfigure provider networks, affecting private cover that serves approximately 16% of the population (~9 million) and a health sector spending near 8–9% of GDP. For Discovery this pressures medical-scheme administration fees, hospital and clinician contracts and claims management. Scenarios range from phased rollout to rapid shifts, creating implementation uncertainty and timing risk. Expect increased lobbying, compliance spend and product redesign to align with new contracting and reimbursement models.
UK health policy and regulator stance
UK health policy and regulator stance reshapes PMI and wellness: NHS England's 2024/25 budget of about £192bn and a waiting list exceeding 7.5m sustain demand for PMI and cash plans, with private cover reaching roughly 10% of the population. FCA Consumer Duty (effective July 2023) and PRA expectations on conduct and fair value increase compliance costs and product governance requirements. Political shifts affecting NHS procurement or vertical integration could expand or constrain partnership and outsourcing opportunities for insurers and providers.
Government incentives for wellness and prevention
Tax incentives and subsidies that lower costs for screenings, vaccinations and fitness programs can raise preventive uptake; WHO reports NCDs cause ~41 million deaths annually (71% of deaths, 2021). Discovery’s shared-value Vitality model, active across 24 markets as of 2024, links rewards to behavior to improve adherence and reduce claims. Public–private partnerships can scale screening and lifestyle programs to cut NCD burden, but success hinges on alignment with budget cycles and rising political appetite for prevention-led savings.
Geopolitical risk and market entry approvals
Geopolitical risk, sanctions and licensing materially shape Discovery’s international expansion: FDA median review ~10 months and EMA centralized review ~210 days set baselines, while 194 WHO member states have divergent regimes; 2024 saw over 30 national elections increasing policy reversal risk, requiring active engagement with regulators and health ministries and contingency plans for sudden regulatory shifts.
- Regulatory timelines: FDA 10m, EMA 210d
- Global scope: 194 WHO states
- Political volatility: 30+ elections in 2024
- Mitigation: regulator/health ministry engagement, contingency planning
FX controls and fiscal policy in core markets
South African exchange controls (R1m annual discretionary allowance), corporate tax 27% and VAT 15%, plus a 5yr CDS ~350bps and 10y bond ~10.5% (mid‑2025), constrain capital mobility and increase dividend repatriation/friction; sovereign risk raises hedging costs and repatriation timing.
- Fiscal tightening: lowers affordability, cuts discretionary spend
- Stimulus: boosts consumption, raises short‑term demand
- Sin taxes: raise prices, reduce consumption, may improve public health
- Treasury: stress tests, pre‑funding, FX hedges, capital planning
NHI reforms, NHS pressure, regulatory delays and SA capital controls risk
NHI reforms, UK NHS pressures and global regulatory timelines (FDA 10m, EMA 210d) create implementation, compliance and contracting risk for Discovery; private cover ~16% (~9m) and health spend ~8–9% GDP amplify market impact. Geopolitical volatility (30+ elections 2024) and SA capital controls (R1m allowance, corp tax 27%, VAT 15%) raise expansion and repatriation costs.
| Metric | Value |
|---|---|
| Private cover (SA) | 16% (~9m) |
| NHS budget 24/25 | £192bn |
| FDA/EMA | 10m / 210d |
| SA tax/controls | Corp 27% VAT 15% R1m |
What is included in the product
Detailed Word Document
Explores how Political, Economic, Social, Technological, Environmental and Legal forces uniquely impact Discovery, with data-backed trends and forward-looking insights to help executives, consultants, and investors identify risks, opportunities, and strategy implications.
Customizable Excel Spreadsheet
A concise, visually segmented PESTLE summary for Discovery that streamlines stakeholder alignment and meeting prep and can be dropped into slides or reports; editable notes let teams tailor insights to region or business line for faster decision-making.
Economic factors
Consumer income and affordability cycles
Consumer income cycles shape lapse rates and product mix: IMF WEO 2025 shows 2024 GDP growth of ~0.8% in South Africa, ~0.3% in the UK and ~3.5% in other EMs, while CPI averaged ~5.8% (SARB) in SA and ~3% (ONS) in the UK, squeezing disposable income and increasing lapses in mid/low-tier products. Scenario models calibrated to 2024 real-wage moves (UK real wages ~+2% y/y; SA stagnation) imply ~0.8 percentage-point rise in lapse rates per -1% real-wage fall and ~0.5–1.2% premium sensitivity, reducing Vitality engagement ~0.6% per -1% real wage; this dictates prioritising flexible pricing and broker/direct digital push where elasticity is highest.
Medical inflation and claims trajectory
South African medical inflation ran near 8–9% in 2024 versus general CPI about 5–6%, lifting Discovery Health loss ratios; utilization rose as elective procedures rebounded ~15% post‑COVID while chronic disease (diabetes/hypertension) prevalence remains elevated (~10–12% adults). Provider tariff negotiations and benefit design levers (formularies, co‑pays) are key; stress tests show a 6–8ppt claims shock could erode margins ~2–3ppt.
Interest rates and investment returns
Interest rate levels drive investment income and set reserving discount rates—US 10‑yr at ~4.2% (June 2025) lifts asset yields and reduces PV of liabilities, improving solvency coverage. Balance sheet duration matching and asset allocation must extend duration into corporates and long govies to hedge liability curves and reduce capital volatility. Guaranteed products and annuities face margin pressure; stress tests assuming a 100 bps cut or a 50–150 bps parallel yield‑curve shift model reserve increases and capital strain.
Employment trends and group benefits demand
Rising unemployment in South Africa (≈33% in 2024) depresses corporate scheme membership and premium volumes as SME take-up falls faster than large corporates; large employers retain group schemes, supporting stable premium pools while SMEs shift to cost‑saving flexible benefits. Wage bills rose ~6% y/y in 2024, driving demand for benefits that control total rewards; employers report wellness programmes deliver ROI in the region of 3:1 to 6:1. Pipeline scenarios: tight labour markets boost uptake and premium growth 3–7% annually; weak labour markets shift volumes toward scaled, modular offerings.
- Employment impact: high unemployment → lower SME membership, stable large-corp retention
- Wage pressure: ~6% wage growth → demand for cost-effective benefits
- Wellness ROI: 3:1–6:1 supports employer investment
- Forecast: tight market +3–7% premiums; weak market → modular SME offerings
Currency volatility and translation risk
Currency moves in ZAR and GBP materially affect Discovery’s reported rand revenues and capital when translating UK earnings and dollar-priced tech costs; USD/ZAR around 18.5 and GBP/ZAR ~23.5 (mid-2025) amplify translation losses on a weaker ZAR.
Hedging policies use forwards and natural offsets from UK liabilities and local underwriting; procurement in hard currency raises operating cost exposure for tech and reinsurers.
Scenario: sustained 20% ZAR depreciation would reduce reported rand equity and inflate imported tech costs materially; volatility spikes increase hedging costs and earnings variance.
- Translation risk: high
- Hedging: active forwards
- Hard-currency procurement: significant
- 20% ZAR fall: material P&L/equity impact
NHI reforms, NHS pressure, regulatory delays and SA capital controls risk
Macroeconomic squeeze: 2024 GDP growth ~0.8% (ZA), ~0.3% (UK) with CPI ~5.8% (ZA) and ~3% (UK) reducing real incomes and raising lapses; calibrated models show ~0.8ppt lapse rise per -1% real‑wage fall. Medical inflation ~8–9% in 2024, lifting loss ratios; SA unemployment ~33% cuts SME scheme volumes. FX and rates: USD/ZAR ~18.5, GBP/ZAR ~23.5 (mid‑2025); US 10yr ~4.2%.
| Metric | Value |
|---|---|
| SA GDP growth (2024) | ~0.8% |
| UK GDP (2024) | ~0.3% |
| CPI SA/UK | 5.8% / 3% |
| Medical inflation (SA 2024) | 8–9% |
| Unemployment SA (2024) | ≈33% |
| USD/ZAR (mid‑2025) | ~18.5 |
| US 10yr (Jun‑2025) | ~4.2% |
What You See Is What You Get
Discovery PESTLE Analysis
The preview shown here is the exact Discovery PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use. What you see is the final file with no placeholders or teasers. After checkout you’ll be able to download this exact document immediately.
